Targeting bone metastasis in prostate cancer with endothelin receptor antagonists

Clinical Cancer Research

Volumn 12, Issue 20 PART 2, 2006, Pages

  Carducci, Michael A ^a   Jimeno, Antonio ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO; UNCLASSIFIED DRUG; ZD 4054;

APOPTOSIS; ASTHENIA; BONE METASTASIS; CANCER GROWTH; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DYSPNEA; HEADACHE; HUMAN; HYPONATREMIA; HYPOTENSION; INFECTION; OSSIFICATION; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RHINITIS; TUMOR CELL; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMANS; MALE; PROSTATIC NEOPLASMS; PYRROLIDINES; RECEPTORS, ENDOTHELIN;

EID: 33750728404     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0929     Document Type: Review

References (44)

1. Fox E, Curt GA, Balis FM. Clinical trial design for target-based therapy. Oncologist 2002;7:401-9.
2. Rubin SA, Levin ER. Clinical review 53: The endocrinology of vasoactive peptides: synthesis to function. J Clin Endocrinol Metab 1994;78:6-10.
3. Bremnes T, Paasche JD, Mehlum A, Sandberg C, Bremnes B, Attramadal H. Regulation and intracellular trafficking pathways of the endothelin receptors. J Biol Chem 2000;275:17596-604.
4. Levin ER. Endothelins. N Engl J Med 1995;333:356-63.
5. Gray GA, Webb DJ. The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther 1996;72:109-48.
6. Bagnato A, Natali PG. Endothelin receptors as novel targets in tumor therapy. J Transl Med 2004;2:16.
7. Obara K, Koide M, Ishikawa T, Tanabe Y, Nakayama K. Protein kinase C δ but not PKC epsilon activity is involved in contractile potentiation by endothelin-1 in the porcine coronary artery. J Cardiovasc Pharmacol 2000;36:S120-1.
8. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signaling by G-protein-coupled receptors. Nature 1996;379:557-60.
9. Jiang ZY, Zhou QL, Chatterjee A, et al. Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. Diabetes 1999;48:1120-30.
10. Battistini B, Chailler P, D'Orléans-Juste P, Brière N, Sirois P. Growth regulatory properties of endothelins. Peptides 1993;14:385-99.
11. Vacca F, Bagnato A, Catt KJ, Tecce R. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 2000;60:5310-7.
12. Clarke JG, Benjamin N, Larkin SW, Webb DJ, Davies GJ, Maseri A. Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol 1989;257:H2033-5.
13. Remuzzi G, Perico N, Benigni A. New therapeutics that antagonize endothelin: promises and frustrations. Nat Rev Drug Discov 2002;1:986-1001.
14. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110-6.
15. Bagnato A, Spinella F, Rosano L. Emerging role of the endothelin axis in ovarian tumor progression. Endocr Relat Cancer 2005;12:761-72.
16. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944-9.
17. Nelson JB, Chan-Tack K, Hedican SP, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996;56:663-8.
18. Papandreou CN, Usmani B, Geng Y, et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998;4:50-7.
19. Nelson JB, Lee WH, Nguyen SH, et al. Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 1997;57:35-7.
20. Usmani BA, Harden B, Maitland NJ, Turner AJ. Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines. Clin Sci (Lond) 2002;103 Suppl 48:314-75.
21. Nelson JB, Nguyen SH, Wu-Wong JR, et al. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 1999;53:1063-9.
22. Chaio JW, Moonga BS,Yang YM, et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 2000;83:360-5.
23. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 2003;100:10954-9.
24. Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer 2003;97:779-84.
25. Pomonis JD, Rogers SD, Peters CM, Ghilardi JR, Mantyh PW. Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception. J Neurosci 2001;21:999-1006.
26. Jarvis MF, Wessale JL, Zhu CZ, et al. ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain. Eur J Pharmacol 2000;388:29-35.
27. Yuyama H, Koakutsu A, Fujiyasu N, et al. Inhibitory effects of a selective endothelin-a receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. J Cardiovasc Pharmacol 2004;44Suppl 1:5479-82.
28. Yuyama H, Koakutsu A, Fujiyasu N, et al. Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain. Eur J Pharmacol 2004;492:177-82.
29. Khodorova A, Navarro B, Jouaville LS, et al. Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. Nat Med 2003;9:1055-61.
30. Godara G, Cannon GW, Cannon GM, Jr., Bies RR, Nelson JB, Pflug BR. Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma. Prostate 2005;65:27-34.
31. Eberl LP, Valdenaire O, Saintgiorgio V, Jeannin JF, Juillerat-Jeanneret L. Endothelin receptor blockade potentiated FasL-induced apoptosis in rat colon carcinoma cells. Int J Cancer 2000;86:182-7.
32. DelBufalo D, DiCastro V, Biroccio A, et al. Endothelin-1 protects ovarian carcinoma cells against pacltiaxel-induced apoptosis: requirement for AKT activation. Mol Pharmacol 2002;61:524-32.
33. Nelson JB, Udan MS, Guruli G, Pflug BR. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia 2005;7:631-7.
34. Rosano L, Varmi M, Salani D, et al. Endothelin-1 induces tumor proteinase activation and invasivenesss of ovarian carcinoma cells. Cancer Res 2001;61:8340-6.
35. Salani D, Taraboletti G, Rosano L, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothetial cells and stimulate neovascularization in vivo. Am J Pathol 2000;157:1703-11.
36. Spinella F, Rosano L, DiCastro V, Natali PG, Bagnato A. Endothelin-1 induces vasculasr endothelial growth factor by increasing hypoxia-inducible factor-1 α in ovarian carcinoma cells. J Biol Chem 2002;277:27850-5.
37. Carducci MA, Nelson JB, Bowling MK, et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 2002;20:2171-80.
38. Zonnenberg BA, Groenewegen G, Janus TJ, et al. Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res 2003;9:2965-72.
39. Ryan CW, Vogelzang NJ, Vokes EE, et al. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res 2004;10:4406-11.
40. Carducci MA, Nelson JB, Saad FF, et al. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: Phase 3 study. In: Proceedings of the 40th American Society of Clinical Oncology Annual Meeting, New Orleans: 2004.
41. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679-89.
42. Nelson JB, Nabulsi AA, Vogelzang NJ, et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 2003;169:1143-9.
43. Schulman C, Dearnaley D, Zonnenberg B, et al. Atrasentan delays disease progression in men presenting with metastatic hormone refractory prostate cancer [abstract]. Presented at XIXth EAU Congress, Vienna: 2004. p. 1057.
44. Morris CD, Rose A, Curwen J, Hughes AM, Wilson DJ, Webb DJ. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 2005;92:2148-52.